Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib

Akt2 is an isoform of Akt, and an association between Akt2 and resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been suggested in pancreatic cancer (PC) in vitro. In this study, we investigated the association between Akt2 expression as evaluated using immu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of oncology 2017-06, Vol.50 (6), p.2049-2058
Hauptverfasser:	Banno, Eri, Togashi, Yosuke, de Velasco, Marco A, Mizukami, Takuro, Nakamura, Yu, Terashima, Masato, Sakai, Kazuko, Fujita, Yoshihiko, Kamata, Ken, Kitano, Masayuki, Kudo, Masatoshi, Nishio, Kazuto
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Care and treatment Cell Line, Tumor Clinical significance Deoxyribonucleic acid Disease-Free Survival DNA Dosage and administration Drug Resistance, Neoplasm - genetics ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Erlotinib Erlotinib Hydrochloride - administration & dosage Erlotinib Hydrochloride - adverse effects Female Gemcitabine Gene Expression Regulation, Neoplastic - drug effects Genomes Humans Inhibitor drugs Kinases Male Middle Aged Mutation Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Phosphatidylinositol 3-Kinases - antagonists & inhibitors Protein Kinase Inhibitors - administration & dosage Proto-Oncogene Proteins c-akt - genetics Studies Targeted cancer therapy Thiazoles - administration & dosage Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!